SI21273A - Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina - Google Patents
Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina Download PDFInfo
- Publication number
- SI21273A SI21273A SI200200187A SI200200187A SI21273A SI 21273 A SI21273 A SI 21273A SI 200200187 A SI200200187 A SI 200200187A SI 200200187 A SI200200187 A SI 200200187A SI 21273 A SI21273 A SI 21273A
- Authority
- SI
- Slovenia
- Prior art keywords
- inclusion bodies
- csf
- biosynthesis
- management
- protein
- Prior art date
Links
- 210000003000 inclusion body Anatomy 0.000 title claims abstract description 178
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 128
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 124
- 239000002243 precursor Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims description 15
- 238000000034 method Methods 0.000 claims abstract description 52
- 238000005406 washing Methods 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 230000014616 translation Effects 0.000 claims abstract 7
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 133
- 238000000855 fermentation Methods 0.000 claims description 55
- 230000004151 fermentation Effects 0.000 claims description 55
- 230000006698 induction Effects 0.000 claims description 47
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 41
- 238000007726 management method Methods 0.000 claims description 37
- 238000004090 dissolution Methods 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000000872 buffer Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000002609 medium Substances 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 27
- 230000008569 process Effects 0.000 claims description 27
- 230000015572 biosynthetic process Effects 0.000 claims description 25
- 239000004202 carbamide Substances 0.000 claims description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims description 18
- 239000007983 Tris buffer Substances 0.000 claims description 18
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 18
- 108700004121 sarkosyl Proteins 0.000 claims description 18
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 18
- 239000003599 detergent Substances 0.000 claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- 239000000411 inducer Substances 0.000 claims description 12
- 108010077895 Sarcosine Proteins 0.000 claims description 9
- 229940043230 sarcosine Drugs 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 7
- 230000004186 co-expression Effects 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 239000007987 MES buffer Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 239000007995 HEPES buffer Substances 0.000 claims description 3
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 claims description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 3
- 229940047122 interleukins Drugs 0.000 claims description 3
- 229940117986 sulfobetaine Drugs 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 239000007991 ACES buffer Substances 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 2
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims description 2
- 239000007996 HEPPS buffer Substances 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 2
- SREKYKXYSQMOIB-UHFFFAOYSA-N N-carbamoylsarcosine Chemical compound NC(=O)N(C)CC(O)=O SREKYKXYSQMOIB-UHFFFAOYSA-N 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- 230000001851 biosynthetic effect Effects 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical group CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 239000013028 medium composition Substances 0.000 claims 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 141
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 21
- 239000002028 Biomass Substances 0.000 description 18
- 238000009825 accumulation Methods 0.000 description 17
- 230000004071 biological effect Effects 0.000 description 17
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 16
- 238000007792 addition Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000008188 pellet Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 12
- 238000004153 renaturation Methods 0.000 description 12
- 239000003398 denaturant Substances 0.000 description 10
- 229940009976 deoxycholate Drugs 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 9
- 229960000723 ampicillin Drugs 0.000 description 9
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 8
- 229940041514 candida albicans extract Drugs 0.000 description 8
- 239000012138 yeast extract Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000010217 densitometric analysis Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000013587 production medium Substances 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012137 tryptone Substances 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108010062867 Lenograstim Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960002618 lenograstim Drugs 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- REEBJQTUIJTGAL-UHFFFAOYSA-N 3-pyridin-1-ium-1-ylpropane-1-sulfonate Chemical compound [O-]S(=O)(=O)CCC[N+]1=CC=CC=C1 REEBJQTUIJTGAL-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- CNXPCGBLGHKAIL-UHFFFAOYSA-N NSDB 211 Chemical compound OCC[N+](C)(C)CCCS([O-])(=O)=O CNXPCGBLGHKAIL-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200200187A SI21273A (sl) | 2002-07-31 | 2002-07-31 | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina |
| PCT/EP2003/006134 WO2004015124A1 (en) | 2002-07-31 | 2003-06-11 | Process for the production of a heterologous protein |
| JP2004526684A JP4703186B2 (ja) | 2002-07-31 | 2003-06-11 | 封入体における高い量の正しく折りたたまれた異種タンパク質の生産方法 |
| EP03783975A EP1527188B1 (en) | 2002-07-31 | 2003-06-11 | Process for the production of increased amounts of correctly folded heterologous protein in inclusion bodies |
| US10/522,826 US20050283000A1 (en) | 2002-07-31 | 2003-06-11 | Process for the production of a heterologous protein |
| AU2003250347A AU2003250347A1 (en) | 2002-07-31 | 2003-06-11 | Process for the production of a heterologous protein |
| DE60331149T DE60331149D1 (de) | 2002-07-31 | 2003-06-11 | Verfahren zur herstellung erhöhter mengen an richtig gefalteten heterologen proteinen in einschlussteilchen |
| AT03783975T ATE456665T1 (de) | 2002-07-31 | 2003-06-11 | Verfahren zur herstellung erhöhter mengen an richtig gefalteten heterologen proteinen in einschlussteilchen |
| SI200331784T SI1527188T1 (sl) | 2002-07-31 | 2003-06-11 | Postopek za pripravo povečanih količin pravilnozvitega heterolognega proteina v inkluzijskih telesih |
| AR20030102713A AR040719A1 (es) | 2002-07-31 | 2003-07-29 | Proceso para la produccion de una proteina heterologa |
| JP2010254743A JP2011078421A (ja) | 2002-07-31 | 2010-11-15 | 封入体における高い量の正しく折りたたまれた異種タンパク質の生産方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200200187A SI21273A (sl) | 2002-07-31 | 2002-07-31 | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI21273A true SI21273A (sl) | 2004-02-29 |
Family
ID=31713326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200200187A SI21273A (sl) | 2002-07-31 | 2002-07-31 | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina |
| SI200331784T SI1527188T1 (sl) | 2002-07-31 | 2003-06-11 | Postopek za pripravo povečanih količin pravilnozvitega heterolognega proteina v inkluzijskih telesih |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200331784T SI1527188T1 (sl) | 2002-07-31 | 2003-06-11 | Postopek za pripravo povečanih količin pravilnozvitega heterolognega proteina v inkluzijskih telesih |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050283000A1 (enExample) |
| EP (1) | EP1527188B1 (enExample) |
| JP (2) | JP4703186B2 (enExample) |
| AR (1) | AR040719A1 (enExample) |
| AT (1) | ATE456665T1 (enExample) |
| AU (1) | AU2003250347A1 (enExample) |
| DE (1) | DE60331149D1 (enExample) |
| SI (2) | SI21273A (enExample) |
| WO (1) | WO2004015124A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI21639A (sl) * | 2003-12-23 | 2005-06-30 | LEK farmacevtska dru�ba d.d. | Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine |
| EP1939212A1 (en) * | 2006-12-20 | 2008-07-02 | LEK Pharmaceuticals D.D. | Organic compounds |
| WO2008096370A2 (en) * | 2007-02-05 | 2008-08-14 | Natco Pharma Limited | An efficient and novel purification method of recombinant hg-csf |
| WO2008133141A1 (ja) * | 2007-04-24 | 2008-11-06 | Toyo Boseki Kabushiki Kaisha | オスモチン組換えタンパク質およびその製造方法、並びにその利用 |
| NZ583276A (en) | 2007-08-27 | 2012-06-29 | Biogenerix Ag | Liquid formulations of granulocyte colony stimulating factor and polymer conjugates |
| US20090294362A1 (en) * | 2008-05-30 | 2009-12-03 | Persson Jonas Par | Stationary phase for hydrophilic interaction chromatography |
| WO2011109556A2 (en) | 2010-03-04 | 2011-09-09 | Pfenex Inc. | Method for producing soluble recombinant interferon protein without denaturing |
| NZ603033A (en) | 2010-04-01 | 2014-06-27 | Pfenex Inc | Methods for g-csf production in a pseudomonas host cell |
| JP5836621B2 (ja) | 2011-03-31 | 2015-12-24 | 株式会社マキタ | 動力工具 |
| HUP1200172A2 (en) | 2012-03-19 | 2013-10-28 | Richter Gedeon Nyrt | Methods for refolding g-csf from inclusion bodies |
| HUP1200171A1 (hu) | 2012-03-19 | 2013-09-30 | Richter Gedeon Nyrt | Módszerek polipeptidek elõállítására |
| ES2751735T3 (es) | 2013-02-12 | 2020-04-01 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| EP3744728A1 (en) | 2013-02-12 | 2020-12-02 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| US20160250298A1 (en) * | 2013-11-01 | 2016-09-01 | Spherium Biomed S.L. | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
| CN104152515B (zh) * | 2014-08-14 | 2019-12-31 | 江苏奥赛康药业有限公司 | 一种制备重组人粒细胞集落刺激因子的培养基及发酵方法 |
| JP2020080727A (ja) * | 2018-11-26 | 2020-06-04 | Ｓｐｉｂｅｒ株式会社 | 目的タンパク質の製造方法 |
| EP4161943A4 (en) * | 2020-06-09 | 2025-01-01 | Icosavax, Inc. | Method of making virus-like particle |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPH0618778B2 (ja) * | 1985-10-04 | 1994-03-16 | 中外製薬株式会社 | 白血球減少症治療剤 |
| IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| DE4037196A1 (de) * | 1990-11-22 | 1992-05-27 | Boehringer Mannheim Gmbh | Verfahren zur reaktivierung von denaturiertem protein |
| EP0832220A1 (en) * | 1995-06-07 | 1998-04-01 | Amgen Inc. | Ob protein compositions and method |
| US5912327A (en) * | 1996-09-30 | 1999-06-15 | Human Genome Sciences, Inc. | Method of purifying chemokines from inclusion bodies |
| AU739796B2 (en) * | 1996-12-27 | 2001-10-18 | Japan Tobacco Inc. | Flower organ-specific gene and its promoter sequence |
| US20020052026A1 (en) * | 1997-10-08 | 2002-05-02 | Steven M. Vicik | Methods of refolding proteins |
| US6677139B1 (en) * | 1999-12-23 | 2004-01-13 | Genecor International, Inc. | Methods for production of proteins in host cells |
| WO2003102013A2 (en) * | 2001-02-23 | 2003-12-11 | Gonzalez-Villasenor Lucia Iren | Methods and compositions for production of recombinant peptides |
| SI21102A (sl) * | 2001-12-19 | 2003-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika |
-
2002
- 2002-07-31 SI SI200200187A patent/SI21273A/sl not_active IP Right Cessation
-
2003
- 2003-06-11 SI SI200331784T patent/SI1527188T1/sl unknown
- 2003-06-11 AT AT03783975T patent/ATE456665T1/de active
- 2003-06-11 AU AU2003250347A patent/AU2003250347A1/en not_active Abandoned
- 2003-06-11 WO PCT/EP2003/006134 patent/WO2004015124A1/en not_active Ceased
- 2003-06-11 EP EP03783975A patent/EP1527188B1/en not_active Expired - Lifetime
- 2003-06-11 US US10/522,826 patent/US20050283000A1/en not_active Abandoned
- 2003-06-11 DE DE60331149T patent/DE60331149D1/de not_active Expired - Lifetime
- 2003-06-11 JP JP2004526684A patent/JP4703186B2/ja not_active Expired - Fee Related
- 2003-07-29 AR AR20030102713A patent/AR040719A1/es unknown
-
2010
- 2010-11-15 JP JP2010254743A patent/JP2011078421A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP4703186B2 (ja) | 2011-06-15 |
| ATE456665T1 (de) | 2010-02-15 |
| WO2004015124A1 (en) | 2004-02-19 |
| EP1527188A1 (en) | 2005-05-04 |
| SI1527188T1 (sl) | 2010-05-31 |
| US20050283000A1 (en) | 2005-12-22 |
| AR040719A1 (es) | 2005-04-20 |
| JP2011078421A (ja) | 2011-04-21 |
| JP2006502708A (ja) | 2006-01-26 |
| DE60331149D1 (de) | 2010-03-18 |
| AU2003250347A1 (en) | 2004-02-25 |
| EP1527188B1 (en) | 2010-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI21273A (sl) | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina | |
| JP2564506B2 (ja) | 異種タンパク質の製造方法 | |
| RU2094439C1 (ru) | Рекомбинантный полипептид pgh(a) с n-концевым аланином | |
| EP1442052B1 (en) | High level constitutive production of anthrax protective antigen | |
| JPS6267032A (ja) | 組換ヒトβ―インターフェロンを含有する医薬組成物及びその製造方法 | |
| MX2009000278A (es) | Replegamiento de proteinas recombinantes. | |
| US4894334A (en) | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria | |
| CN104603280A (zh) | 生产多肽的方法 | |
| US7034119B2 (en) | Method for recombinant production of polypeptides | |
| Dehaghani et al. | An efficient purification method for high recovery of recombinant human granulocyte colony stimulating factor from recombinant E. coli | |
| CN102869767B (zh) | 干扰素α5的制备方法 | |
| NL2035702B1 (en) | Trachinotus ovatus b cell lymphoma-2 gene, trachinotus ovatus b cell lymphoma-2 protein, plasmid, and application of trachinotus ovatus b cell lymphoma-2 gene | |
| ES2281822T3 (es) | Vectores de expresion, celulas huesped transformadas y procedimiento de fermentacion para la produccion de polipeptidos recombinantes. | |
| US7514403B2 (en) | Process for the stabilization of proteins in an aqueous solution comprising cysteine in a concentration between 150 and 220mM | |
| RU2321424C1 (ru) | ПРЕПАРАТ, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pSX70, КОДИРУЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО ЧЕЛОВЕЧЕСКОГО ГРАНУЛОЦИТ-КОЛОНИЙСТИМУЛИРУЮЩЕГО ФАКТОРА (Г-КСФ), ШТАММ Escherichia coli SX70-ПРОМЫШЛЕННЫЙ ШТАММ ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ЧЕЛОВЕЧЕСКОГО Г-КСФ И СПОСОБ ПРОМЫШЛЕННОГО ПОЛУЧЕНИЯ Г-КСФ | |
| WO2008096368A2 (en) | A novel process for production of recombinant human g-csf | |
| CN119662605B (zh) | 多肽及其用途、制备多肽的方法、组合物或试剂盒 | |
| RU2680886C1 (ru) | Рекомбинантная плазмида pFM-GCSF5, обеспечивающая экспрессию синтетического гранулоцитарного колониестимулирующего фактора человека, штамм бактерий Escherichia coli FM-GCSF - продуцент рекомбинантного гранулоцитарного колониестимулирующего фактора человека и способ его получения | |
| US20190077842A1 (en) | Method For Producing A Recombinant Protein With Reduced Impurities | |
| EP2912173B1 (en) | Process for preparation and purification of recombinant human oncostatin m protein | |
| US5210029A (en) | Method of producing interleukin-2 | |
| CN111087478B (zh) | 一种重组胶原蛋白及其制备方法 | |
| US20160031932A1 (en) | Refolding of proteins | |
| WO2022223505A1 (en) | Control of n-terminal truncation by methionine supplementation | |
| EP1833846A2 (en) | Method for production of a therapeutically pure granulocyte macrophage - colony stimulating factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| KO00 | Lapse of patent |
Effective date: 20120830 |